Mark Andersen, MD
Family Medicine · Omaha, NENPI 1972525251
Payments from drug & device makers
Across 387 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$918
- AstraZeneca$902
- Amgen$598
- Novo Nordisk$493
- Pfizer$308
- plus $1K from 29 others
What the payments were for
- Food & beverage$5,71198%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $1,131 |
| Lilly USA, LLC | 92 | $918 |
| AstraZeneca | 42 | $902 |
| Amgen | 43 | $598 |
| Novo Nordisk | 34 | $493 |
| Pfizer | 20 | $308 |
| Astellas Pharma US Inc | 6 | $190 |
| Boehringer Ingelheim | 13 | $180 |
| Johnson & Johnson(2 entities) | 9 | $153 |
| Novartis | 8 | $136 |
| Otsuka America Pharmaceutical, Inc. | 7 | $120 |
| Bayer | 6 | $92 |
| Abbott | 4 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Seqirus USA Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Organon | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Merck | 1 | $13 |
| Gilead | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$296
- FARXIGA$296
- BYDUREON$187
- QTERN$187
- BREZTRI AEROSPHERE$109
How this compares
$5,820 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $84,893 |
| EliquisApixaban | 80 | $65,777 |
| OzempicSemaglutide | 22 | $28,646 |
| XareltoRivaroxaban | 14 | $20,514 |
| TrulicityDulaglutide | 14 | $13,240 |
| JardianceEmpagliflozin | 14 | $9,258 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $4,227 |
| Rosuvastatin Calcium | 224 | $2,353 |
| Colesevelam Hcl | 24 | $2,206 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,940 |
| Metoprolol Succinate | 117 | $1,705 |
| Gabapentin | 65 | $1,626 |
| Atorvastatin Calcium | 233 | $1,612 |
| Pantoprazole Sodium | 99 | $1,542 |
| SynthroidLevothyroxine Sodium | 21 | $1,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $918 | $98,13383 claims |
| PfizerEliquis | $308 | $65,77780 claims |
| Novo NordiskOzempic | $493 | $28,64622 claims |
| Johnson & JohnsonXarelto | $153 | $20,51414 claims |
| Boehringer IngelheimJardiance | $180 | $9,25814 claims |
| AbbVieSynthroid | $1,131 | $1,46621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Kenneth BladOmaha$1.6M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
- Gregston NelsonOmaha$147K
- Birgit KhandalavalaOmaha$107K
- John HallgrenOmaha$94K
- Gerard StanleyOmaha$50K
- Kent JohnsonOmaha$16K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.